RNN Key Stats
- Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Confe... May 20
- REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 9
- Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A ... Apr 2
- REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principa... Mar 29
- REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 22
- Rexahn Pharmaceuticals to Present at the 25th Annual ROTH Conference Business Wire Mar 11
- Rexahn Pharmaceuticals Provides Key Goals for 2013 noodls Feb 19
- Rexahn Pharma Issues 2013 Goals Benzinga Feb 19
- Rexahn says to continue RX-3117 development with Teva Feb 19
- U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Marketwire Feb 12
RNN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Rexahn Pharmaceuticals is down 12.73% over the last year vs S&P 500 Total Return up 27.81%, ARCA biopharma down 0.31%, and Sangamo BioSciences up 76.94%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for RNN
Pro Report PDF for RNN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download RNN Pro Report PDF
Pro Strategies Featuring RNN
Did Rexahn Pharmaceuticals make it into our Pro Portfolio Strategies?